



## Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

May 29, 2026

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- [Pharvaris](#) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the [European Academy of Allergy and Clinical Immunology \(EAACI\) Annual Congress 2026](#), to be held from June 12-15, 2026, in Istanbul, Turkey.

Details of the presentations are as follows:

- **Title:** Oral Deucricitbant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDE-3 Trial  
**Presenter:** Mauro Cancian, M.D., Ph.D.  
**Format:** Oral Presentation  
**Date, time:** Friday, June 12, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)
- **Title:** Clinical Cardiovascular Safety Assessment of Oral Deucricitbant  
**Presenter:** Anne Lesage, Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
- **Title:** A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema  
**Presenter:** Evangelia Pardali, Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
- **Title:** Evaluations of Safety Margins and Response to Deucricitbant Extended-Release (XR) Tablet in Combination with Deucricitbant Immediate-Release (IR) Capsule  
**Presenter:** Anne Lesage, Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
- **Title:** Oral Deucricitbant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDE-3 Trial  
**Presenter:** Philip Li, M.D., FRCP  
**Format:** Poster Presentation  
**Date, time:** Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
- **Title:** RAPIDE-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucricitbant for On-Demand Treatment of Hereditary Angioedema Attacks  
**Presenter:** Anna Valerieva, M.D., Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
- **Title:** Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucricitbant for Prophylaxis in Hereditary Angioedema  
**Presenter:** Markus Magerl, M.D.  
**Format:** Flash Talk  
**Date, time:** Saturday, June 13, 2026, 5:45-6:30 p.m. TRT (10:45-11:30 a.m. EDT)
- **Title:** CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucricitbant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema  
**Presenter:** Markus Magerl, M.D.  
**Format:** Flash Talk  
**Date, time:** Saturday, June 13, 2026, 5:45-6:30 p.m. TRT (10:45-11:30 a.m. EDT)

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: [ir.pharvaris.com/news-events/events-presentations](https://ir.pharvaris.com/news-events/events-presentations).

### About Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in

bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris' aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucricitibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucricitibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucricitibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit <https://pharvaris.com/>.

Contact Maggie Beller Vice President, Head of Corporate and Investor Communications [maggie.beller@pharvaris.com](mailto:maggie.beller@pharvaris.com)